Novartis Phase III ORION-4 trial of pelacarsen misses primary endpoint

Novartis reported that its Phase III ORION-4 trial evaluating pelacarsen failed to achieve its primary endpoint. Full results will be presented at an upcoming American Heart Association meeting and published in a medical journal.

Detected & updated continuously · Source: Nebula